3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
76
Urinary Bladder Neoplasms
20
Neoplasms
11
Carcinoma, Transitional Cell
8
Non-Muscle Invasive Bladder Neoplasms
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Testicular Neoplasms
3
Recurrence
3
Prostatic Neoplasms, Castration-Resistant
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Kidney Neoplasms
3
Colorectal Neoplasms
3
Carcinoma in Situ
3
Adenocarcinoma
3
Acute Kidney Injury
3
Uterine Cervical Neoplasms
2
Prostate CA
2
Melanoma
2
Liver Neoplasms
2
Kidney Failure, Chronic
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Gallbladder Neoplasms
2
Critical Illness
2
Colonic Neoplasms
2
Agnosia
2
Interventions
Melphalan
1
Lenograstim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Castrate Resistant Prostate Cancer
×
Genitourinary
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled